Automated reporting of primaquine dose efficacy, tolerability and safety for Plasmodium vivax malaria using a systematic review and individual patient data meta-analysis
Year: 2025
Type: review
Study designs: Systematic Review, Meta-Analysis
Abstract: BACKGROUND: The antirelapse efficacy of primaquine is related to the total dose administered, whereas the risks of haemolysis and gastrointestinal intolerance are associated with the daily dose administered. National Malaria Control Programmes require local information on efficacy, tolerability and safety to optimize antimalarial treatment policies for Plasmodium vivax malaria control and elimination efforts. METHODS: A living systematic review identified efficacy studies of uncomplicated P. vivax malaria including patients treated with daily primaquine regimens, published since January 1, 2000. Available data were pooled and an R Shiny app was developed to integrate statistical analyses performed using R and Stata that assessed the impact of primaquine mg/kg dose on efficacy, hematological safety and gastrointestinal tolerability. RESULTS: As of January 16, 2025, a total of 9,270 individual patient data records from 41 studies have been collated into the standardized repository. Open-access automated reports were generated for user-selected countries or regions to investigate location specific effects of primaquine dose on efficacy, safety and tolerability. The reports include visual and tabular displays of the outcomes. CONCLUSIONS: These automated reports leverage a large database to provide accessible data for national and regional policy makers and researchers to assess the clinical consequences of different primaquine regimens in different endemic settings. The reports will inform local and regional policy decisions and research priorities in vivax-endemic areas.
Source: Malaria Journal
Authors: Peta Edler, Megha Rajasekhar, David J. Price, Ishag Adam, Ghulam Rahim Awab, Bridget E. Barber, Larissa W. Brasil, Nathália N. Chamma-Siqueira, Cindy S. Chu, Liwang Cui, André Daher, Margarete do Socorro M. Gomes, Lilia Gonzalez-Ceron, Matthew J. Grigg, Harin Karunajeewa, Marcus V. G. Lacerda, Simone Ladeia-Andrade, Toby Leslie, Benedikt Ley, Kartini Lidia, Alejandro Llanos-Cuentas, Rhea J. Longley, Laurens Manning, Daniel Abebe Mekonnen, Wuelton Marcelo Monteiro, Brioni R. Moore, Francois Nosten, Ayodhia Pitaloka Pasaribu, Dhelio B. Pereira, Jeanne Rini Poespoprodjo, Sasithon Pukrittayakamee, Komal Raj Rijal, Kavitha Saravu, André M. Siqueira, Inge Sutanto, Walter R. J. Taylor, Pham Vinh Thanh, Kamala Thriemer, José Luiz F. Vieira, Nicholas J. White, Asnakew K. Yeshiwondim, Lina M. Zuluaga-Idarraga, Philippe J. Guerin, Julie A. Simpson, Ric N. Price, Robert J. Commons, WorldWide Antimalarial Resistance Network (WWARN) Vivax Primaquine Dosing Efficacy, Tolerability and Safety Study Group, Tesfay Abreha, Bipin Adhikari, Mohammad Shafiul Alam, Nicholas M. Anstey, Ashenafi Assefa, J. Kevin Baird, Sarah C. Boyd, Nguyen Hoang Chau, Nicholas P. J. Day, Tamiru Shibiru Degaga, Arjen M. Dondorp, Annette Erhart, Marcelo U. Ferreira, Endalamaw Gadisa, Najia Ghanchi, Prakash Ghimire, Justin A. Green, Mohammad Anwar Hassanzai, Jimee Hwang, Wasif Ali Khan, Gavin C. K. W. Koh, Rishikesh Kumar, Asrat Hailu Mekuria, Ivo Mueller, Mohammad Nader Naadim, Suaine C. Negreiros, Erni J. Nelwan, Anielle de Pina-Costa, Mark Rowland, Jetsumon Sattabongkot, Guilherme Suarez-Kurtz, Fitsum G. Tadesse, Giselle M. R. Viana, Lorenz von Seidlein, Timothy William, Charles J. Woodrow, Sze-Ann Woon, Adugna Woyessa
Institutions: The University of Melbourne, Peter Doherty Institute, Qassim University, Mahidol University, Mahidol Oxford Tropical Medicine Research Unit, Afghan International Islamic University, QIMR Berghofer Medical Research Institute, Charles Darwin University, Menzies School of Health Research, Fundação de Medicina Tropical, Universidade do Estado do Amazonas, Ministério da Saúde, Instituto Evandro Chagas, University of Oxford, Shoklo Malaria Research Unit, University of South Florida, Fundação Oswaldo Cruz, Universidade Federal do Amapá, Western Health, The University of Texas Medical Branch at Galveston, University of Lisbon, Universidade Nova de Lisboa, HealthNet TPO, London School of Hygiene & Tropical Medicine, University of Nusa Cendana, Universidad Peruana Cayetano Heredia, Instituto de Medicina Tropical Alexander von Humboldt, Walter and Eliza Hall Institute of Medical Research, The Kids Research Institute Australia, The University of Western Australia, Fiona Stanley Hospital, Haramaya University, Armauer Hansen Research Institute, Curtin University, Universitas Sumatera Utara, Universidade Federal de Rondônia, Universitas Gadjah Mada, Rumah Sakit Umum Daerah Kabupaten Mimika, Tribhuvan University, Manipal Academy of Higher Education, Kasturba Medical College, Manipal, University of Indonesia, National Institute of Malariology, Parasitology and Entomology, Universidade Federal do Pará, World Health Organization, Universidad de Antioquia, Infectious Diseases Data Observatory, Grampians Health, Columbia University, International Centre for Diarrhoeal Disease Research, University of North Carolina at Chapel Hill, Ethiopian Public Health Institute, Royal Brisbane and Women's Hospital, Oxford University Clinical Research Unit Indonesia, Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Arba Minch University, MRC Unit the Gambia, Universidade de São Paulo, Aga Khan University, GlaxoSmithKline (United Kingdom), Health Protection and Research Organisation, Centers for Disease Control and Prevention, U.S. President's Malaria Initiative, Northwick Park Hospital, Rajendra Memorial National Institute of Health Research, Addis Ababa University, University of Gondar, Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo, Universidade Federal Fluminense, Instituto Nacional de Câncer - INCA, Centro Universitário do Pará, Subang Jaya Medical Centre, Queen Elizabeth Hospital, Royal Perth Hospital
Language: English
Topic: Malaria Research and Control
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,890
Funders: Bill and Melinda Gates Foundation, GlaxoSmithKline, World Health Organization, London School of Hygiene and Tropical Medicine, Wellcome Trust, Universidad Internacional de La Rioja, Tribhuvan University, Kasturba Medical College, Manipal, University of Oxford, Indian Council of Medical Research, Curtin University of Technology, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Mahidol University, China Scholarship Council, Haramaya University, Universidad de Antioquia, Universidade de São Paulo, Universidade de Lisboa, Universitas Indonesia, Fundação Oswaldo Cruz, Universidade Federal do Pará, University of Gondar, Addis Ababa University, Universitas Gadjah Mada, Universitas Sumatera Utara, Universidade do Estado do Amazonas, Fiona Stanley Hospital, Centers for Disease Control and Prevention, University of North Carolina at Chapel Hill, President's Malaria Initiative, Medical Research Council, National Health and Medical Research Council, Faculty of Tropical Medicine, Mahidol University, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Mailman School of Public Health, Columbia University
Awards: Addressing the threat of emerging zoonotic malaria in our region, Leveraging naturally acquired immune responses to malaria to advance control and elimination of this disease, Malaria volunteer infection studies for the advancement of antimalarial therapeutics, Defining the role of primaquine in malaria elimination., G4332815903, Optimising radical cure for vivax malaria to accelerate malaria elimination, Optimising treatment and prevention strategies to accelerate malaria elimination, Advancing the radical cure of Plasmodium vivax malaria through optimal antimalarial regimens, Improving the treatment of malaria., Interventions to eliminate Plasmodium vivax malaria, G9000302673
OpenAlex ID: W4416224749